News | May 14, 2007

Confirmatory Trial Developed for Acorn’s Cardiac Support Device

May 15, 2007 — Acorn Cardiovascular has announced that the FDA will consider approval of the CorCap Cardiac Support Device (CSD) based on the successful completion of a prospective confirmatory trial that addresses issues raised by the Medical Device Dispute Resolution Panel and the Circulatory System Devices Panel. The company had completed a 300-patient prospective, randomized pivotal trial and submitted data to the FDA in 2004. However, the two panels voted against approval for the CorCap CSD in December 2006 and June 2005, respectively, citing the need for additional clinical data.

Since the MDDRP decision last year, Acorn Cardiovascular has worked closely with Dan Schultz, M.D., director of the Center for Devices and Radiological Health (CDRH), and Bram Zuckerman, M.D., director of the Division of Cardiovascular Devices, to design a confirmatory trial that would alleviate the concerns of the panels. Dr. Schultz is the highest-ranking official at FDA with responsibility for the assessment of medical devices.

The confirmatory trial will assess a patient population that demonstrated the greatest clinical benefit in the pivotal trial. If Acorn meets the success criteria for the confirmatory trial, it is expected that FDA may be able to approve the device without engaging a third advisory panel. It will involve 50 patients in key investigational sites selected from the original 29 pivotal trial site locations.

Dr. Michael A. Acker, chief of the Division of Cardiac Surgery at the University of Pennsylvania, will serve as principal investigator (PI) of the confirmatory trial. Sites should start enrolling patients in summer 2007, with the aim of completing enrollment in early 2008. Following a six-month follow-up period and pending positive results, the company anticipates approval to occur by the end of 2008 or the beginning of 2009.

For more information visit www.acorncv.com.

Related Content

FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Overlay Init